163 related articles for article (PubMed ID: 22767311)
1. Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
Zampino R; Costa G; Barillari M; Adinolfi LE; Marrone A
Infez Med; 2012 Jun; 20(2):117-9. PubMed ID: 22767311
[TBL] [Abstract][Full Text] [Related]
2. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
Papastergiou V; Skorda L; Lisgos P; Karatapanis S
Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
[No Abstract] [Full Text] [Related]
3. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
[TBL] [Abstract][Full Text] [Related]
4. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
5. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM
Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109
[TBL] [Abstract][Full Text] [Related]
8. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
Jain S; Midha V; Sood A
Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
[No Abstract] [Full Text] [Related]
9. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
10. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
11. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil.
Mendes-Corrêa MC; Bittar RS; Salmito N; Oiticica J
Braz J Infect Dis; 2011; 15(1):87-9. PubMed ID: 21412597
[TBL] [Abstract][Full Text] [Related]
12. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
Fabrizi F; Aghemo A; Moroni G; Passerini P; D'Ambrosio R; Martin P; Messa P
Dig Dis Sci; 2014 Mar; 59(3):691-5. PubMed ID: 24318802
[No Abstract] [Full Text] [Related]
13. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
[TBL] [Abstract][Full Text] [Related]
14. [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin].
Kim YH; Han WS; Lee SJ; Oh SN; Choi DW; Byun KS; Yeon JE
Korean J Hepatol; 2007 Sep; 13(3):419-22. PubMed ID: 17898559
[TBL] [Abstract][Full Text] [Related]
15. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
16. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
17. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
Nomura H; Miyagi Y; Tanimoto H; Yamashita N; Ito K; Masaki N; Mizokami M
J Gastroenterol Hepatol; 2012 Sep; 27(9):1461-6. PubMed ID: 22554247
[TBL] [Abstract][Full Text] [Related]
18. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
Tahata Y; Hiramatsu N; Oze T; Morishita N; Harada N; Yamada R; Yakushijin T; Mita E; Hagiwara H; Yamada Y; Ito T; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Irishio K; Kato M; Hikita H; Sakamori R; Miyagi T; Yoshida Y; Tatsumi T; Hamasaki T; Hayashi N; Takehara T
J Gastroenterol; 2016 Mar; 51(3):252-9. PubMed ID: 26223482
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
20. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
